DR. CHRISTOPHER CANNOVA, M.D.

BETHESDA, MD

Research Active
Orthopaedic Surgery NPI registered 21+ years 4 publications 1996 – 2019 NPI: 1235134560
CattleMicrobial Sensitivity TestsStructure-Activity RelationshipCell LineEnzyme InhibitorsCell DivisionHeLa CellsPlasmodium falciparumAntiprotozoal AgentsHistone Deacetylase InhibitorsPeptides, CyclicEimeria tenellaBiological FactorsCombinatorial Chemistry TechniquesFusarium

Practice Location

10215 FERNWOOD RD
BETHESDA, MD 20817-1184

Phone: (301) 530-1010

What does CHRISTOPHER CANNOVA research?

Dr. Cannova studies how different medical treatments can improve patient outcomes, particularly in knee surgeries and infections caused by parasites. For knee surgeries, he examines patient-specific implants to see how they compare to traditional implants in helping patients recover better and regain knee function. In his other line of research, he investigates a drug called apicidin that targets parasitic infections. By modifying this compound, he aims to create more potent treatments that specifically affect parasites while being safer for human cells.

Key findings

  • In the study of knee implants, both patient-specific and standard implants showed similar improvement rates in knee function post-surgery, with only one patient needing an adjustment for a custom implant compared to two for a standard implant.
  • Some modified versions of the compound apicidin were found to be up to 1,000 times more effective at blocking specific enzymes related to protozoan parasites, indicating a significant advancement in treatment efficacy.
  • Apicidin demonstrated strong effectiveness against malaria parasites in test subjects, which is critical given the rising ineffectiveness of existing treatments for such infections.

Frequently asked questions

Does Dr. Cannova study knee surgery?
Yes, Dr. Cannova researches the outcomes of different types of knee implants to help patients recover better after surgery.
What treatments has Dr. Cannova researched?
He has researched treatments for knee surgery and developed new antiprotozoal agents to target parasitic infections.
Is Dr. Cannova's work relevant to patients with infections?
Yes, his research on apicidin could lead to better and more effective treatments for patients suffering from parasitic infections.
What types of infections does Dr. Cannova focus on?
He focuses on infections caused by parasites, including those that lead to diseases like malaria.
How do the knee implants studied by Dr. Cannova compare?
Both patient-specific and standard knee implants showed similar results, with low adjustment needs after surgery, indicating that both types are effective.

Publications in plain English

Early outcomes of patient-specific posterior stabilized total knee arthroplasty implants.

2019

Journal of orthopaedics

Wheatley B, Nappo K, Fisch J, Rego L, Shay M +1 more

Plain English
This study looked at the results of total knee implants that are specifically made to fit individual patients, compared to standard implants. Researchers found that both types had similar outcomes, with one patient needing manipulation under anesthesia in the custom group and two in the standard group. Overall, there was no significant difference in recovery scores for either type, showing that patient-specific implants work as well as regular implants. Who this helps: Patients needing knee replacement surgery.

PubMed

Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1.

2001

Bioorganic & medicinal chemistry letters

Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM +11 more

Plain English
This study focused on a compound called apicidin, which can block specific enzymes in both human and protozoan cells. Researchers found that by modifying apicidin, they created new versions that are much more effective, with some variants being up to 1,000 times stronger at blocking these enzymes. This is important because it could lead to better treatments for diseases caused by protozoan infections. Who this helps: This benefits patients with protozoan infections, as well as doctors treating these conditions.

PubMed

Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2.

2001

Bioorganic & medicinal chemistry letters

Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM +11 more

Plain English
This study looked at a drug called apicidin, which was discovered by Merck and can disrupt specific enzymes related to both human and parasite cells. Researchers found ways to modify apicidin to create new versions that are much more effective at targeting parasites while being less likely to affect human cells. This matters because it could lead to better treatments for infections caused by parasites. Who this helps: Patients suffering from parasitic infections.

PubMed

Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase.

1996

Proceedings of the National Academy of Sciences of the United States of America

Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM +10 more

Plain English
Researchers studied a new substance called apicidin, found in fungi, which has shown strong effects against certain harmful parasites, specifically those that cause diseases like malaria. In tests with mice, apicidin effectively fought against the malaria parasite, indicating that it works well in living organisms, not just in a lab setting. This research is essential because many existing treatments are losing effectiveness, and new solutions are urgently needed to combat serious infections. Who this helps: Patients suffering from parasitic infections and doctors fighting these diseases.

PubMed

Frequent Co-Authors

S L Colletti R W Myers S J Darkin-Rattray A M Gurnett P M Dulski J J Allocco T M Crumley D M Schmatz P T Meinke S Galuska

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.